INTRODUCTION
Neurological complications occur in 30-75% of all cases of systemic lupus erythematosus (SLE)' (1) . It has been reported that some immuinological findings, suich as deposition of immune complexes in the choroid plexus, are associated wvith neuropsychiatric manifestations (2) . It has recently been suggested that antibodies directed to neuronal antigens, including lymphocvtotoxic antibodies crossreactive wvith the brain (3, 4) , have some pathogenetic relevance to these neurologic manifestations. It has also been found that immunoglobulin (Ig)M antibodies cytotoxic to human neuroblastoma cell lines (5) and IgG antibodies reacting against neuroblastoma by indirect immunofluorescence (6) exist in the sera of SLE patients with neurological complications.
Recent studies in our laboratory identified that an antibody, antibrain-associated T cell antigen, which is present in heterologous antisera raised against brain tissue and which usually also reacts against T lymphocytes is directed against a neutral glycolipid, "asialo GM," (7) . In view of the fact that asialo GM1 from brain has a strong antigenicity, we in SLE included definite neurologic (both central and peripheral) or psychiatric abnormalities not attributable to non-SLE etiologies. Disorders thought to be due to infection or corticosteroid therapy were excluded. All the sera were stored at -80°C and centrifuged at 7,500 g for 1 h before use.
Glycolipids. GM, was isolated from bovine brain by a combination of anion-exchange chromatography and high performance adsorption chromatography (8) . Asialo GM, was prepared from GM, by treatment with 1 N formic acid at 80°C for 1 h, and then purified by chromatography on DEAE-Sephadex A-25 and Silica Gel 60 (Merck & Co., Inc., Rahway, N.J.). Asialo GM2 was prepared from guinea pig erythrocytes. The purity of each ganglioside preparation was checked by thin-layer chromatography and chemical analysis as described previously (7) . Galactocerebroside was also prepared from bovine brain.
Detection of antibodies. Serial dilutions of antiserum in phosphate-buffered saline (0.02 ml) were mixed with 0.02 ml of antigen containing 1 txg of glycolipid in the form of lecithin: cholesterol micelles in a microtiter plate (7). The reaction was performed at room temperature for 60 min, and the mixture was centrifuged at 200 g for 5 min. The flocculated immune complexes were easily perceived in agglutinated form. The agglutination titer was usually decided by someone who was unaware of the diagnoses. To check the sensitivity and the reproducibility ofthe immunoassay, antiasialo GM,, antiasialo GM2, and antibrain-associated T cell antigen raised in rabbits were usually used as positive control. A titration experiment using affinity column-purified rabbit antiasialo GM1 revealed that at least 0.2 ,ug/ml of antibody is required to show positive reaction by this assay. Detection of antibodies to doublestranded DNA (anti-DNA) was carried out by the radioimmunoassays described by Keiser (9, 10) . Naturally occuring T cMl toxic autoantibody was detected as described previously (11) . The cells were analyzed by a fluorescenceactivated cell sorter (FACS II, B-D FACS Systems, Mountain View, Calif.).
Fractionation ofsera. The sera from two patients (patients 1 and 2) were fractionated by Sephadex G-200 chromatography in phosphate-buffered saline, (pH 7.2). IgM and IgG in the eluate were examined by immunoelectrophoresis, and the major fractions of IgM and IgG were separately pooled and concentrated. The sera from patients 1-4 were also fractionated with a protein A-Sepharose CL-4B affinity column. The effluent and the eluate, adjusted to pH 7.0, were collected for use. Each fraction was examined by immunoflocculation test with asialo GM1 as described above.
RESULTS
The sera were examined for their antibody activities against various glycolipid molecules purified from bovine brain tissues. The sera from 14 Table I . No association between the titer of antiasialo GM, and other autoantibodies such as natural T cell toxic autoantibody and anti-DNA was observed.
To determine whether or not this antiglycolipid antibody is related to the occurrence ofthe neurological involvement in SLE patients, a time-course study was peiformed by measuring the titers of antiasialo GM1 at various times in course of the disease. Actually, the serum samples of the patients that had been collected at several-month intervals were examined retrospectively after the history of seizure was obtained. Fig. 1 represents the changes of the serum antibody titer from four patients with severe neurological manifestations, which occurred only during the period shown in Fig. 1 started to appear, and that the titer increased again after the seizure had ceased. In all four cases examined, their time courses showed a similar pattern, whereas no antibody activity was observed in the sera of epilepsy obtained at various intervals after the seizure. Thus the appearance and decrease of this antibody was shown to have a close relationship to the onset of the neurological manifestations in SLE. A study was performed to learn what immunoglobulin class this antiglycolipid antibody belongs to. The sera from two SLE patients having high antiasialo GM1 activity were fractionated on a Sephadex G-200 column and the two fractions corresponding to IgM and IgG were collected and concentrated for analysis ofantiasialo GM1 activity. As depicted in Fig. 2 (12) reported that the injection of heterologous antiserum against brain gangliosides directly into the brain caused an epileptic seizure. Since the preceding blood sample was drawn several months before the seizure, one cannot be sure just when the fall in antibody occurred in relation to the seizure or, for that matter, how rapidly the levels were restored. Though it is not at present possible to detect glycolipid antigen in the sera by any immunological means, it may be postulated that antigen is released at the time of seizure, thereby masking or removing the preexisting antibody.
The mechanisms that produce this autoantibody in SLE are unknown. However, in addition to the fact that asialo GM, is highly immunogenic (7), several laboratories have found that various types of lymphoid cells are able to react with antiasialo GM, (13, 14) . Therefore, it may be possible that SLE patients initially respond to this antigen expressed on lymphoid cells. Alternatively, antigen may be released from the brain into the circulation and produce immunization. Although further studies are needed to define the pathogenic role of this autoantibody, the detection of this antibody may be useful in clinical diagnosis and treatment.
